在报告和传达临床试验结果时实现估计目标框架的益处——一些建议
本文针对ICH E9(R1)估计目标框架在临床试验结果报告中的实施提出建议与考量,旨在提升报告透明度以支持解读与决策。建议基于在方案中实施估计目标框架后与临床试验团队合作报告过程的实践经验,并通过两个案例说明其主要应用于向监管机构提交的药品科学评估报告,并延伸至科学期刊发表。
要点
- 研究结果报告应清晰描述特定医学条件下干预措施的获益与风险,而不仅总结设计、方法和数据。
- ICH E9(R1)估计目标框架旨在使报告的「治疗效应」更加清晰,但利益相关方仍在学习如何以最有价值的方式实施。
- 本文基于实践经验提出在结果报告中实施估计目标框架的建议,主要应用于监管评估报告并延伸至期刊发表。
核心结论
- 本文为在临床试验结果报告中实施估计目标框架提供建议与考量,以实现其提升解读与决策透明度的全部潜力。
研究设计与样本
- 本文为基于在方案中实施估计目标框架后与临床试验团队合作报告过程的实践经验所提出的建议与考量,并通过两个案例研究进行说明。
主要发现
- 研究结果报告用于支持上市许可、充实标签信息,并为学术发表、试验登记和面向医生与患者的推广信息提供依据。
- ICH E9(R1)关于估计目标和敏感性分析的附录提供了旨在使报告的「治疗效应」更加清晰的框架。
- 在实践中,利益相关方仍在学习如何 embrace 估计目标框架及其以最有价值方式影响研究结果报告。
临床怎么用
- 本文建议的主要应用场景是向监管机构提交的药品科学评估报告,直接影响临床研究报告和申报文件,并将延伸至科学期刊发表。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Reports of the results of clinical studies are integral to regulatory decision making. They are used to support marketing authorization, to substantiate labeling information, and to inform academic publications, trial postings, and promotional messages intended to communicate study results to doctors and patients. Therefore, beyond summarizing the study design, methods, and data, study reports should provide clear descriptions of the benefits and risks of an intervention for a given medical condition. The ICH E9(R1) addendum on estimands and sensitivity analysis in clinical trials provides a framework aiming for more clarity about the reported "treatment effects." In practice, stakeholders are still learning how to embrace the estimand framework and how it impacts the reporting of study results in the most value-adding manner. This paper provides recommendations and considerations for implementing the estimand framework in the reporting of results to realize its full potential of increased transparency for interpretation and decision-making. These recommendations are based on practical experiences of working with clinical trial teams through the reporting process following implementation of the estimand framework in the protocol. As illustrated by two case studies, the primary application is in reporting studies for the scientific evaluation of medicines by regulatory agencies, directly impacting clinical study reports and submission documents, and will also extend to publications in scientific journals.
引用
- Lanius V, Glocker B, Lösch C, et al. Realizing the benefits of the estimand framework when reporting and communicating clinical trial results-some recommendations. Trials. 2025. PMID: 40640873. doi:10.1186/s13063-025-08915-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。